JP2021523096A5 - - Google Patents
Info
- Publication number
- JP2021523096A5 JP2021523096A5 JP2020556807A JP2020556807A JP2021523096A5 JP 2021523096 A5 JP2021523096 A5 JP 2021523096A5 JP 2020556807 A JP2020556807 A JP 2020556807A JP 2020556807 A JP2020556807 A JP 2020556807A JP 2021523096 A5 JP2021523096 A5 JP 2021523096A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- pharmaceutical composition
- composition according
- protein
- binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671963P | 2018-05-15 | 2018-05-15 | |
| US62/671,963 | 2018-05-15 | ||
| US201962804931P | 2019-02-13 | 2019-02-13 | |
| US62/804,931 | 2019-02-13 | ||
| PCT/US2019/032271 WO2019222252A1 (en) | 2018-05-15 | 2019-05-14 | Dosing regimens for targeted tgf-b inhibition for use in treating cancer in treatment naive subjects |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021523096A JP2021523096A (ja) | 2021-09-02 |
| JP2021523096A5 true JP2021523096A5 (cg-RX-API-DMAC10.html) | 2022-05-18 |
Family
ID=68540945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020556807A Pending JP2021523096A (ja) | 2018-05-15 | 2019-05-14 | 未治療対象において癌を治療する際に使用するための標的ｔｇｆ−β阻害のための投与計画 |
Country Status (12)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3158047A1 (en) * | 2019-12-11 | 2021-06-17 | Yunying CHEN | Bi-functional antibody against pd-l1 and tgf? |
| WO2021218883A1 (zh) * | 2020-04-28 | 2021-11-04 | 神州细胞工程有限公司 | 一种TGFβR2胞外区截短分子、其与抗EGFR抗体的融合蛋白及其抗肿瘤用途 |
| EP4194002A4 (en) * | 2020-07-24 | 2024-08-14 | Mabwell (Shanghai) Bioscience Co., Ltd. | TGF-BETA RII MUTANT AND ASSOCIATED FUSION PROTEIN |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201216649D0 (en) * | 2012-09-18 | 2012-10-31 | Univ Birmingham | Agents and methods |
| MY186864A (en) * | 2013-03-12 | 2021-08-26 | Biocon Ltd | Fusion immunomodulatory proteins and methods for making same |
| HRP20210977T1 (hr) * | 2014-02-10 | 2021-09-17 | Merck Patent Gmbh | Ciljano inhibiranje tgf beta |
| SG10201913538VA (en) * | 2015-11-23 | 2020-02-27 | Five Prime Therapeutics Inc | Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment |
| JP7573365B2 (ja) * | 2016-08-12 | 2024-10-25 | メルク パテント ゲーエムベーハー | 癌の併用療法 |
-
2019
- 2019-05-14 BR BR112020021082-0A patent/BR112020021082A2/pt not_active Application Discontinuation
- 2019-05-14 KR KR1020207035552A patent/KR20210009339A/ko not_active Withdrawn
- 2019-05-14 AU AU2019271065A patent/AU2019271065A1/en not_active Abandoned
- 2019-05-14 CN CN201980032533.9A patent/CN112118858A/zh active Pending
- 2019-05-14 SG SG11202011148VA patent/SG11202011148VA/en unknown
- 2019-05-14 MX MX2020011638A patent/MX2020011638A/es unknown
- 2019-05-14 CA CA3096844A patent/CA3096844A1/en active Pending
- 2019-05-14 WO PCT/US2019/032271 patent/WO2019222252A1/en not_active Ceased
- 2019-05-14 EP EP19804320.0A patent/EP3813868A4/en not_active Withdrawn
- 2019-05-14 JP JP2020556807A patent/JP2021523096A/ja active Pending
- 2019-05-15 TW TW108116801A patent/TW202003577A/zh unknown
-
2020
- 2020-11-11 US US17/095,377 patent/US20210061899A1/en not_active Abandoned